Lady Mireille Gillings

CEO, HUYA Bioscience International

Lady Mireille Gillings is the founder, President, CEO and Executive Chair of HUYA Bioscience International, the privately held global leader in accelerating development of  biopharma innovation originating in China. Lady Gillings is a pioneer in establishing extensive collaborations with Chinese academic institutions and commercial organizations to create value in worldwide markets for China-sourced biopharma compounds. As a visionary leader with 20 years’ experience in the biotech sector – including drug development, preclinical study design and academic partnering programs – Lady Gillings has made substantial contributions to neurological and neurodegenerative disease research, including a focus on neuroactive steroids.

Lady Gillings serves on the board of directors of Quintiles (NYSE: Q), a Fortune 500 company and the world’s largest provider of biopharmaceutical development and commercial outsourcing services. She is the first woman appointed to the board of Quintiles since the company’s privatization and subsequent IPO. In addition, she is Co-founder and non-Executive Vice Chair of GHO Capital, a European private equity fund specializing in global health opportunities; and serves on the Board of Directors of Senté Inc, a private science-based skincare company.

Educated in Canada, the Netherlands, France, and the USA, Lady Gillings has a Ph.D. in neuroscience from Radboud University Nijmegen and has completed post-doctoral fellowships at Bordeaux University and Scripps Research Institute. She speaks fluent English, Dutch, French and Spanish.

Pablo Legorreta

Founder and Chief Executive Officer, Royalty Pharma

Mr. Legorreta founded Royalty Pharma in 1996, after creating and managing two “proof of principle” investment vehicles in 1993 and 1994 that invested in royalty interests in two leading biotechnology products. Prior to founding these investment vehicles, Mr. Legorreta spent ten years at Lazard Frères where he provided cross-border merger and acquisition and corporate finance advisory services to US and European corporations. Mr. Legorreta joined Lazard Frères et Cie in Paris in 1988, then moved to Lazard Frères & Co in New York in 1990.

Mr. Legorreta currently serves as a Director of Giuliani SpA and is a founding member of Boston Children’s Hospital Medical Research Council, as well as a member of the Board of Trustees of The Allen-Stevenson School. He received a degree in industrial engineering from Universidad Iberoamericana.

François Maisonrouge

Chairman, Pasteur Foundation
Senior Managing Director, Evercore Partners

At Evercore, Mr. Maisonrouge was involved in advising Wyeth on its sale to Pfizer, Sanofi-aventis on its purchase of Merck’s 50% stake in Merial including an option to potentially merge Merial with Intervet / Schering-Plough Animal Health in the future, TPG on its acquisition of IMS Health, De Ruiter on its sale to Monsanto, Bracco on its acquisition of E-Z-Em, and the sale of Optonol to Alcon.

Prior to joining Evercore, Mr. Maisonrouge was a Managing Director and Chairman of Life Sciences at Credit Suisse where he worked extensively in the fields of pharmaceuticals, specialty pharmaceuticals, biotechnology and medical technology. At Credit Suisse, Mr. Maisonrouge was responsible for leading the firm’s relationships with large healthcare clients such as Johnson & Johnson, Schering-Plough, Wyeth, GlaxoSmithKline, Roche and Teva, most notably in executing mergers and acquisitions and capital raising transactions.

Mr. Maisonrouge has an M.S. in Engineering from Ecole Centrale de Lyon and an M.B.A. from Harvard Business School. He is a member of the Board of Advisors of the Harvard Business School Health Care Initiative, and was awarded France’s “Ordre National du Merite” in 2003. In 2014, Mr. Maisonrouge was awarded the rank of Chevalier de la Légion d'honneur. He resides in New York City.